[ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط]
Myron M. Levine, Gordon Dougan, Michael F. Good, Margaret A. Liu,
Gary J. Nabel, James P. Nataro, Rino Rappuoli, "New Generation Vaccines,
Fourth Edition"
Informa Healthcare | ISBN: 1420060732 | December 9, 2009 | 1168 pages |
PDF | 13.2 MB
Amazon Price: $454.28
The past 10 years have seen an expanded scientific and commercial
interest in the potential of new vaccines. Scientific advances have
created new tools for developing vaccines for diseases for which no
vaccines exist. The complete genomic sequence of a pathogen provides a
catalogue of potential vaccine components. Improved techniques of
protein purification and peptide synthesis facilitate the
identification, isolation, and engineering of candidate vaccines. Novel
adjuvants, formulations, and delivery systems to induce an optimal
immune response have been developed. Recombinant-DNA techniques
facilitate the construction of live vaccines, live vectors, or nucleic
acid vaccines into which a gene coding for the vaccine antigen can be
cloned. The vaccine market is also growing rapidly, and by the year 2000
it is estimated that it will reach a sales volume twice or even three
times that of the early 1990s. Average annual growth rates of the
vaccine business could, in the next few years, be above 10 percent,
which will obviously stimulate research and development in academic
institutions and commercial pharmaceutical companies.
[ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط]
Myron M. Levine, Gordon Dougan, Michael F. Good, Margaret A. Liu,
Gary J. Nabel, James P. Nataro, Rino Rappuoli, "New Generation Vaccines,
Fourth Edition"
Informa Healthcare | ISBN: 1420060732 | December 9, 2009 | 1168 pages |
PDF | 13.2 MB
Amazon Price: $454.28
The past 10 years have seen an expanded scientific and commercial
interest in the potential of new vaccines. Scientific advances have
created new tools for developing vaccines for diseases for which no
vaccines exist. The complete genomic sequence of a pathogen provides a
catalogue of potential vaccine components. Improved techniques of
protein purification and peptide synthesis facilitate the
identification, isolation, and engineering of candidate vaccines. Novel
adjuvants, formulations, and delivery systems to induce an optimal
immune response have been developed. Recombinant-DNA techniques
facilitate the construction of live vaccines, live vectors, or nucleic
acid vaccines into which a gene coding for the vaccine antigen can be
cloned. The vaccine market is also growing rapidly, and by the year 2000
it is estimated that it will reach a sales volume twice or even three
times that of the early 1990s. Average annual growth rates of the
vaccine business could, in the next few years, be above 10 percent,
which will obviously stimulate research and development in academic
institutions and commercial pharmaceutical companies.
[ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط]
